ZB
BPMC

Zions Bancorporation’s Blueprint Medicines BPMC Stock Holding History

Zions Bancorporation’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-58
Closed -$2.54K – 931
2022
Q4 		$2.54K Buy
+58
New +$2.78K ﹤0.01% 933

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Zions Bancorporation's BPMC Position: Q1 2023 in Review

Zions Bancorporation sold out of Blueprint Medicines (BPMC) in Q1 2023, closing a stake of 58 shares — an estimated $2.54K sold.

Zions Bancorporation first reported a position in BPMC in Q4 2022 and held it in 1 quarter. The position peaked at $2.54K in Q4 2022. 214 funds tracked by Wall St. Rank hold BPMC as of Q1 2023.

  • Zions Bancorporation reported no remaining Blueprint Medicines position as of Q1 2023 after selling out during the quarter.
  • Zions Bancorporation sold 58 Blueprint Medicines shares in Q1 2023, an estimated $2.54K.
  • Zions Bancorporation first reported a position in Blueprint Medicines in Q4 2022 and held it in 1 quarter.
  • Zions Bancorporation's Blueprint Medicines position peaked at $2.54K in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2023.

Based on Zions Bancorporation's 13F filing for Q1 2023, filed 10 May 2023.